Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prediction of the responsiveness to pharmacological chaperones: lysosomal human alpha-galactosidase, a case of study.

Orphanet journal of rare diseases - 7 Dec 2010

Andreotti Giuseppina, Guarracino Mario R, Cammisa Marco, Correra Antonella, Cubellis Maria Vittoria

Abstract excerpt

BACKGROUND: The pharmacological chaperones therapy is a promising approach to cure genetic diseases. It relies on substrate competitors used at sub-inhibitory concentration which can be administered orally, reach difficult tissues and have low cost. Clinical trials are currently carried out for F...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to 1-Deoxynojirimycin
Share to alpha-Galactosidase
Share to Catalytic Domain

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fabry Disease

Share to Lysosomes

Share to Molecular Chaperones

Share to Predictive Value of Tests

Share to Structure-Activity Relationship

Source

Open in PubMed Open full text

Identifiers

PMID: 21138548
DOI: 10.1186/1750-1172-5-36
PMCID: PMC3016270

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-21138548-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prediction of the responsiveness to pharmacological chaperones: lysosomal human alpha-galactosidase, a case of study.PMID 21138548Read ↗

Identification of an Allosteric Binding Site on Human Lysosomal Alpha-Galactosidase Opens the Way to New Pharmacological Chaperones for Fabry Disease.Semantic proximity Read ↗

Fabry_CEP: a tool to identify Fabry mutations responsive to pharmacological chaperones.Semantic proximity Read ↗

Protein structural features predict responsiveness to pharmacological chaperone treatment for three lysosomal storage disordersSemantic proximity Read ↗

Functional characterisation of alpha-galactosidase a mutations as a basis for a new classification system in fabry disease.Semantic proximity Read ↗

Challenging popular tools for the annotation of genetic variations with a real case, pathogenic mutations of lysosomal alpha-galactosidaseSemantic proximity Read ↗

Taming molecular flexibility to tackle rare diseases.Semantic proximity Read ↗

Prediction of response of mutated alpha-galactosidase A to a pharmacological chaperone.Semantic proximity Read ↗

Human α-Galactosidase A Mutants: Priceless Tools to Develop Novel Therapies for Fabry Disease.Semantic proximity Read ↗

Molecular damage in Fabry disease: characterization and prediction of alpha-galactosidase A pathological mutations.Semantic proximity Read ↗

Functional and pharmacological evaluation of novel GLA variants in Fabry disease identifies six (two de novo) causative mutations and two amenable variants to the chaperone DGJ.Semantic proximity Read ↗

The New Pharmacological Chaperones PBXs Increase α-Galactosidase A Activity in Fabry Disease Cellular Models.Semantic proximity Read ↗

A thermodynamic assay to test pharmacological chaperones for Fabry disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.